Android app on Google Play

MKM Partners Sees Amarin's (AMRN) Patents Protecting Vascepa into 2030

September 5, 2012 10:46 AM EDT Send to a Friend
Get Alerts AMRN Hot Sheet
Price: $1.30 -3.7%

Rating Summary:
    4 Buy, 14 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 24 | New: 21
Trade AMRN Now!
Join SI Premium – FREE
MKM Partners reiterated their Buy rating and $21.50 price target on Amarin Corporation (NASDAQ: AMRN) following recent USPTO updates on patents.

Yesterday, Amarin announced that the USPTO gave a Notice of Allowance for the MARINE trial Patent Application 13/282,145. Today, the company announced that the USPTO gave a Notice of Allowance for two additional MARINE Patent Applications, 12/702,889 and 13/349,153.

"These patents would protect Vascepa into 2030 and are clearly important for Amarin to secure a partnership or acquisition," analyst Jon LeCroy, M.D. said.

Commenting on Amarin's 'Patent Estate' the firm notes seven Vascepa patent applications have been issued or allowed or are in advanced stages of
prosecution with the United States Patent and Trademark Office, in addition to 25 other U.S. patent applications pending. Amarin also recently received an Intention to Grant letter for a MARINE method of use patent in Europe. W"e expect six patent applications to be granted in the U.S. over the next several months," he sad.

LeCroy expects expect the FDA to grant Vascepa NCE status in mid-September and said the August delay mild positive. "The next Orange Book update is expected on September 14 or potentially on September 21, if the first week of September is not considered a full week due to the Labor Day holiday," he notes.

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $14.64 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments

Add Your Comment